News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated
